Knights of Columbus Asset Advisors LLC Invests $1.07 Million in Kymera Therapeutics, Inc. $KYMR

Knights of Columbus Asset Advisors LLC purchased a new stake in shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR) in the third quarter, according to the company in its most recent filing with the SEC. The fund purchased 18,891 shares of the company’s stock, valued at approximately $1,069,000.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Mirae Asset Global Investments Co. Ltd. boosted its position in shares of Kymera Therapeutics by 9.9% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,764 shares of the company’s stock valued at $156,000 after buying an additional 248 shares during the last quarter. Farther Finance Advisors LLC raised its position in Kymera Therapeutics by 642.9% in the 2nd quarter. Farther Finance Advisors LLC now owns 624 shares of the company’s stock valued at $27,000 after buying an additional 540 shares during the last quarter. PNC Financial Services Group Inc. lifted its stake in Kymera Therapeutics by 506.6% during the 2nd quarter. PNC Financial Services Group Inc. now owns 922 shares of the company’s stock valued at $40,000 after acquiring an additional 770 shares in the last quarter. Franklin Resources Inc. boosted its holdings in Kymera Therapeutics by 2.5% during the 2nd quarter. Franklin Resources Inc. now owns 33,649 shares of the company’s stock worth $1,468,000 after acquiring an additional 822 shares during the last quarter. Finally, Osaic Holdings Inc. grew its stake in shares of Kymera Therapeutics by 18,050.0% in the 2nd quarter. Osaic Holdings Inc. now owns 1,089 shares of the company’s stock worth $48,000 after acquiring an additional 1,083 shares in the last quarter.

Analyst Ratings Changes

A number of research firms recently weighed in on KYMR. Barclays raised their price target on shares of Kymera Therapeutics to $133.00 and gave the company an “overweight” rating in a research report on Tuesday. Leerink Partners boosted their target price on Kymera Therapeutics from $70.00 to $118.00 and gave the stock an “outperform” rating in a research note on Monday, December 8th. Guggenheim started coverage on Kymera Therapeutics in a report on Monday, November 3rd. They issued a “buy” rating and a $90.00 target price for the company. UBS Group upgraded Kymera Therapeutics to a “strong-buy” rating in a report on Thursday, December 4th. Finally, Wall Street Zen upgraded Kymera Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, November 8th. Two research analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Buy” and an average target price of $117.00.

Insider Buying and Selling at Kymera Therapeutics

In other news, insider Jared Gollob sold 49,307 shares of Kymera Therapeutics stock in a transaction dated Monday, December 8th. The shares were sold at an average price of $88.67, for a total value of $4,372,051.69. Following the completion of the transaction, the insider owned 109,992 shares in the company, valued at $9,752,990.64. This trade represents a 30.95% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Nello Mainolfi sold 30,000 shares of the business’s stock in a transaction that occurred on Wednesday, December 31st. The shares were sold at an average price of $78.06, for a total transaction of $2,341,800.00. Following the completion of the sale, the chief executive officer directly owned 663,077 shares in the company, valued at approximately $51,759,790.62. This trade represents a 4.33% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders sold 420,895 shares of company stock valued at $37,778,351. Insiders own 16.01% of the company’s stock.

Kymera Therapeutics Trading Down 1.7%

Shares of NASDAQ KYMR opened at $72.69 on Friday. The stock has a fifty day simple moving average of $75.62 and a two-hundred day simple moving average of $59.82. Kymera Therapeutics, Inc. has a 1-year low of $19.44 and a 1-year high of $103.00. The firm has a market cap of $5.23 billion, a price-to-earnings ratio of -20.25 and a beta of 2.21.

Kymera Therapeutics (NASDAQ:KYMR) last issued its quarterly earnings results on Tuesday, November 4th. The company reported ($0.90) EPS for the quarter, missing analysts’ consensus estimates of ($0.71) by ($0.19). The firm had revenue of $2.76 million for the quarter, compared to analysts’ expectations of $23.15 million. Kymera Therapeutics had a negative net margin of 674.81% and a negative return on equity of 32.92%. Analysts forecast that Kymera Therapeutics, Inc. will post -2.79 EPS for the current year.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body’s natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company’s proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company’s pipeline emphasizes immunology and oncology.